Tin Tin Htar Myint, Findlow Jamie, Balmer Paul, Swerdlow David
Vaccine Medical Development and Scientific/Clinical Affairs, Pfizer Inc, Paris, France.
Vaccine Medical Development and Scientific/Clinical Affairs, Pfizer Ltd, Tadworth, UK.
Epidemiol Infect. 2024 Dec 5;152:e157. doi: 10.1017/S0950268824001535.
Serogroup epidemiology of invasive meningococcal disease (IMD) is constantly evolving, varying by time and location. Surveillance reports have indicated a rise in meningococcal serogroup Y (MenY) in some regions in recent years. This systematic literature review explores the evolving epidemiology of MenY IMD globally based on review of recent articles and national surveillance reports published between 1 January 2010 and 25 March 2021. Generally, MenY incidence was low (<0.2/100,000) across all ages in most countries. The reported incidence was more frequent among infants, adolescents, and those aged ≥65 years. More than 10% of all IMD cases were MenY in some locations and time periods. Implementation of vaccination evolved over time as the rise in MenY IMD percentage occurred. Cases decreased in countries with quadrivalent vaccine programs (e.g., United Kingdom, the Netherlands, United States, and Australia), whereas the MenY burden increased and made up a large proportion of cases in areas without vaccine programs. Continuous monitoring of epidemiologic changes of IMD is essential to establish MenY burden and for implementation of prevention strategies.
侵袭性脑膜炎球菌病（IMD）的血清群流行病学在不断演变，随时间和地点而变化。监测报告显示，近年来脑膜炎球菌血清群Y（MenY）在一些地区有所增加。本系统文献综述基于对2010年1月1日至2021年3月25日期间发表的近期文章和国家监测报告的回顾，探讨了全球MenY IMD不断演变的流行病学情况。一般来说，大多数国家所有年龄段的MenY发病率都很低（<0.2/100,000）。报告的发病率在婴儿、青少年和65岁及以上人群中更为常见。在某些地点和时间段，所有IMD病例中有超过10%是MenY。随着MenY IMD百分比的上升，疫苗接种的实施也随着时间的推移而演变。在实施四价疫苗计划的国家（如英国、荷兰、美国和澳大利亚），病例数有所下降，而在没有疫苗计划的地区，MenY负担增加，且在病例中占很大比例。持续监测IMD的流行病学变化对于确定MenY负担和实施预防策略至关重要。
